← 返回

TCGA 转录组 TIL 免疫特征的全癌种比较分析

英文原题:A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures.

查看英文原题

A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures.

PubMed 2025/08/07(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

通过基础科学研究和癌症基因组图谱(TCGA)数据分析来理解肿瘤微环境的努力,已促成从TIL(肿瘤浸润淋巴细胞)中创建独特的免疫转录组特征。然而,尚无泛癌分析以总生存期(OS)或无进展间期(PFI)为终点来比较这些特征的预后性能。我们汇编了一个包含146个TIL免疫特征的文库,并评估了基因特征评分与33种肿瘤类型中9,961份可用TCGA样本的OS和PFI的相关性。Zhang CD8 TCS在泛癌范围内预测OS和PFI方面表现出更高的准确性;然而,在不同癌症类型和生殖细胞来源之间观察到变异性。聚类分析汇总了一组六个特征(Oh.Cd8.MAIT、Grog.8KLRB1、Oh.TIL_CD4.GZMK、Grog.CD4.TCF7、Oh.CD8.RPL、Grog.CD4.RPL32),其与OS和PFI的关联可能在多种肿瘤中保守。

展开英文摘要原文

Efforts to understand the tumor microenvironment through basic science research and the cancer genome atlas (TCGA) data analysis have led to the creation of unique immune transcriptomic signatures from tumor-infiltrating lymphocytes (TIL).

However, no pan-cancer analysis has been conducted to compare the prognostic performance of these signatures using overall survival (OS) or progression-free interval (PFI) as endpoints.

We compiled a library of 146 TIL-immune signatures and evaluated gene signature score correlation with OS and PFI for 9,961 available TCGA samples across 33 tumor types. Zhang CD8 TCS demonstrated higher accuracy in prognosticating both OS and PFI across the pan-cancer landscape; however, variability was seen across cancer types and germ cell origin.

Cluster analysis compiled a group of six signatures (Oh. Cd8. MAIT, Grog. 8KLRB1, Oh. TIL_CD4. GZMK, Grog. CD4. TCF7, Oh. CD8. RPL, Grog. CD4. RPL32) whose association with OS and PFI could potentially be conserved across multiple neoplasms.

论文信息

作者
Hitscherich KJ、Nousome D、Dinerman AJ、Dulemba V、Lowery FJ、Nilubol N
第一作者单位
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 112 Kendrick Place, Unit 34, Gaithersburg, Bethesda, MD, 20878, USA. kylehitsche@gmail.com.United States
通讯作者单位
Endocrine Surgery Section, Surgical Oncology Program, National Cancer Institute, NIH, Bethesda, MD, USA. naris.nilubol@nih.gov.United States
文献类型
对照研究
期刊
Cancer immunology, immunotherapy : CII2025 Aug 7
原文标识
PubMed 40773142 · DOI 10.1007/s00262-025-04102-3